These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 3139779)

  • 21. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection.
    Frimodt-Møller N
    Dan Med Bull; 1988 Oct; 35(5):422-37. PubMed ID: 3066588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses.
    Scotty NC; Brooks DE; Schuman Rose CD
    Am J Vet Res; 2008 Jan; 69(1):101-7. PubMed ID: 18167094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of a ticarcillin-clavulanic acid combination in severe infections in adults].
    Lacut JY; Quentin C; Cardoso-Mendes I; Dupon M
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):591-5. PubMed ID: 3937132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A predictive parameter of antibacterial efficacy in vivo, based on efficacy in vitro and pharmacokinetics.
    Mattie H
    Scand J Infect Dis Suppl; 1990; 74():133-6. PubMed ID: 2129065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments in antimicrobial therapy.
    Parry MF
    Del Med J; 1978 Jan; 50(1):33-8. PubMed ID: 631383
    [No Abstract]   [Full Text] [Related]  

  • 31. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
    Novelli A; Fallani S; Cassetta MI; Arrigucci S; Mazzei T
    J Chemother; 2002 Dec; 14(6):584-90. PubMed ID: 12583550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.
    Brogden RN; Pinder RM; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 12(3):166-200. PubMed ID: 789045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic combinations in the treatment of experimental Staphylococcus aureus infection.
    Steigbigel RT; Greenman RL; Remington JS
    J Infect Dis; 1975 Mar; 131(3):245-51. PubMed ID: 1127254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
    Todisco T; Eslami A; Baglioni S; Sposini T; Tascini C; Sommer E; Knoch M
    J Aerosol Med; 2000; 13(1):11-6. PubMed ID: 10947319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience.
    Hoffa DE
    Ther Drug Monit; 1989 Sep; 11(5):574-9. PubMed ID: 2815234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.